Eli Lilly hits $1 trillion market value, a first for a health-care company
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
The drugmaker may not continue to lag the market for much longer.
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Can AI Drive Peloton's Comeback?
The market is hopping with interesting news.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
2 No-Brainer Healthcare Stocks to Buy Now
These two healthcare stocks scan as bargains right now.
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Pfizer's weight management pipeline just got a boost.
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control - Novo Nordisk ( NYSE:NVO )
Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S ( NYSE:NVO ) , saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by ...
2 Giant Healthcare Stocks to Buy Hand Over Fist in November
Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds. it will survive.
Is Pfizer Stock a Buy After This $10 Billion Acquisition?
The company has been on an acquisition spree for years, and this one may be the most important yet.
Deal Dispatch: WBD, Bill.com, C3 AI Auctions Shake Market - C3.ai ( NYSE:AI ) , BILL Holdings ( NYSE:BILL )
An auction is underway for Bill.com ( NYSE:BILL ) . The business-payments firm, according to Bloomberg, tapped a financial adviser to solicit bids. The sale follows activist pressure from Starboard Value, a firm known for buying up stakes in public companies to get deal processes going.
Ozempic Maker Novo Nordisk Faces Board Shakeup - Novo Nordisk ( NYSE:NVO )
On Friday, Novo Nordisk A/S' ( NYSE:NVO ) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Metsera ( NASDAQ:MTSR ) , Pfizer ( NYSE:PFE )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Why Is Everyone Talking About Novo Nordisk Stock?
There is hardly a dull moment for the drugmaker these days.
Why Is BioNTech Stock Falling Today? - Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Pfizer ( NYSE:PFE ) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE ( NASDAQ:BNTX ) . It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report.
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?
Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.
3 Healthcare Stocks Topping a 2025 List of Dividend Yields
Turn health into wealth with these three high-yielding dividend stocks.
2 Strong Healthcare Stock Picks for Value Investors
Value-driven plays abound in the top healthcare stocks.
Why Metsera's Share Price Is Plummeting This Week
The biotech start-up's stock had been rising rapidly in 2025.
Pfizer and Novo Nordisk's $10bn battle over weight-loss drugs
The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington ...
AMD, OKLO, APP, VKTX, NVO: 5 Trending Stocks Today - Advanced Micro Devices ( NASDAQ:AMD )
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30. These are the top stocks that gained the attention of retail traders and investors ...
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S ( NYSE:NVO ) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc ( NASDAQ:MTSR ) . What Happened: According to Reuters, Pfizer Inc ( NYSE:PFE ) won the bidding war against Novo Nordisk and will purchase Metsera for $10 billion.
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera - Pfizer ( NYSE:PFE )
SAN DIEGO, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. ( NASDAQ: MTSR ) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. ( ...
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Where Will Pfizer Be in 3 Years?
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Centene ( NYSE:CNC ) , ProFrac Holding ( NASDAQ:ACDC )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1.5% on Monday. Shares of Monday.Com Ltd ( NASDAQ:MNDY ) fell sharply in pre-market trading ahead of quarterly earnings. Analysts expect the Tel Aviv, Israel-based company to report quarterly earnings at 88 ...
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Autozi Internet Tech ( NASDAQ:AZI ) , BIO-key International ( NASDAQ:BKYI )
Shares of Viasat Inc ( NASDAQ:VSAT ) rose sharply in pre-market trading after the company reported second-quarter financial results. Viasat posted adjusted earnings of 9 cents per share, beating market estimates of a loss of 62 cents per share.
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera.
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Metsera ( NASDAQ:MTSR ) , Eli Lilly ( NYSE:LLY )
Pfizer Inc. ( NYSE:PFE ) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. ( NASDAQ:MTSR ) , beating out Novo Nordisk A/S ( NYSE:NVO ) after a heated bidding war that captivated Wall Street.
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy - Comcast ( NASDAQ:CMCSA ) , Walt Disney ( NYSE:DIS )
Miyoko Schinner - the chef and activist who pioneered artisanal vegan cheese - is mounting a bid to buy back Miyoko's, the plant-based dairy brand she founded in 2014 and was ousted from three years ago.
Why Novo Nordisk Stock Is Sinking This Week
The global drugmaker is facing some headwinds related to tough competition.
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Is the fourth time the charm for this Danish pharmaceutical giant?
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Metsera ( NASDAQ:MTSR ) , Novo Nordisk ( NYSE:NVO ) , Pfizer ( NYSE:PFE )
The Delaware Chancery Court denied Pfizer Inc.'s ( NYSE:PFE ) request for a temporary restraining order to prevent Metsera, Inc. ( NASDAQ:MTSR ) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S ( NYSE:NVO ) .
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
The highest dose of Eli Lilly's weekly injection helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month.
Novo, Pfizer Battling Over Future Of Weight-Loss Drugs - Viking Already Owns It - Metsera ( NASDAQ:MTSR ) , Novo Nordisk ( NYSE:NVO ) , Pfizer ( NYSE:PFE )
Pfizer Inc's ( NYSE:PFE ) lawsuit. Novo Nordisk A/S' ( NYSE:NVO ) counterbid. And in the middle of it all - a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue - Metsera ( NASDAQ:MTSR )
Adding more drama to Metsera Inc.'s ( NASDAQ:MTSR ) acquisition deal, Novo Nordisk A/S ( NYSE:NVO ) increased the deal proposal to $62.20 per share in cash, up from $56.50. Metsera said the amended proposal constitutes a "Superior Company Proposal."
Pfizer ( PFE ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, Nov. 4, 2025 at 10 a.m. ETChairman & Chief Executive Officer - Albert BourlaContinue reading ...
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools
Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.
Metsera says Novo Nordisk's new bid for obesity drugmaker is 'superior' to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior ...
